iCAD Offers ROI Analysis Based On Real-World Results From Its ProFound Breast AI Suite At AHRA Annual Meeting
Portfolio Pulse from Happy Mohamed
iCAD, Inc. (NASDAQ:ICAD) is showcasing its ProFound AI Suite for breast cancer detection at the AHRA 2023 annual meeting. The suite includes ProFound AI Detection®, ProFound AI® Density Assessment, and ProFound AI® Risk. The company is also offering an ROI tool to help organizations measure the return on investment for adopting ProFound AI. Several healthcare providers, including Midstate Radiology Associates, Kettering Health, and Naugatuck Valley Radiology, have reported increased efficiency, standardized assessments, and improved patient care after adopting iCAD's solutions.

July 10, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
iCAD's ProFound AI Suite is being showcased at a major industry event and has been adopted by several healthcare providers, which could increase its visibility and adoption rate.
The showcasing of iCAD's ProFound AI Suite at a major industry event increases its visibility among potential customers. Positive testimonials from existing users could also encourage more healthcare providers to adopt the suite, potentially boosting iCAD's revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100